Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-β-cyclodextrin

AAPS PharmSciTech

Volumn 9, Issue 4, 2008, Pages 1102-1109

  Ribeiro, Andreza ^a,b   Figueiras, Ana ^b   Santos, Delfim ^a   Veiga, Francisco ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

2 hydroxypropyl cyclodextrin; Cyclodextrins; Inclusion complexes; Methyl cyclodextrin; Miconazole

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; MICONAZOLE; ANTIFUNGAL AGENT; BETA CYCLODEXTRIN DERIVATIVE; METHYL-BETA-CYCLODEXTRIN;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG STABILITY; EVAPORATION; FREEZE DRYING; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; SOLID PHASE SYNTHESIS; SOLID STATE; SPRAY DRYING; X RAY DIFFRACTION; CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SOLUBILITY;

ANTIFUNGAL AGENTS; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; MICONAZOLE; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 63649163814     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9143-8     Document Type: Article

References (33)

1. T. Loftsson, and M. E. Brewster. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1017-1025 (1996).
2. J. Szejtli. Introduction and general overview cyclodextrin chemistry. Chem. Rev. 98:1743-1753 (1998).
3. V. J. Stella, and R. A. Rajewski. Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 14:556-567 (1997).
4. T. Loftsson, and E. Brewster. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliver. Rev. 59:645-666 (2007).
5. J. Pitha. Amorphous water soluble derivatives of cyclodextrins: From test tube to patient. J. Control Release. 6:309-313 (1987).
6. A. R. Hedges. Industrial applications of cyclodextrins. Chem. Rev. 98:2035-2044 (1998).
7. F. W. Merkus, J. C. Verhoef, E. Marttin, S. G. Romeijn, W. A. V. D. Kuy, and H. G. Schipper. Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. 36:41-57 (1999).
8. M. Masson, T. Loftsson, G. Masson, and E. Stefansson. Cyclodextrins as permeation enhancers: Some theoretical evaluations and in vitro testing. J. Control Release. 59:107-118 (1999).
9. L. Boulmedarat, A. Bochot, S. Lesieur, and E. Fattal. Evaluation of buccal methyl-beta-cyclodextrin toxicity on human oral epithelial cell culture model. J. Pharm. Sci. 94:1300-1309 (2005).
10. M. E. Davis, and M. E. Brewster. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Dis. 3:1023-1035 (2004).
11. T. Loftsson, and M. Masson. Cyclodextrins in topical drug formulations: Theory and practice. Int. J. Pharm. 225:15-30 (2001).
12. G. Piel, B. Evrard, M. Fillet, G. Llabres, and L. Delattre. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins. Int. J. Pharm. 169:15-22 (1998).
13. M. Pedersen, S. Pedersen, A. M. Sorensen, A. Scarpelline, S. Skytte, and C. Slot. Polymorphism of miconazole during preparation of solid systems of the drug and b-cyclodextrins. Pharma. Acta Helv. 68:43-47 (1993).
14. S. Tenjarla, P. Puranajoti, R. Kasina, and T. Mandal. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J. Pharm. Sci. 87:425-429 (1998).
15. J. L. Bononi. Beta-cyclodextrin miconazole complex and beta-cyclodextrin econazole complex and their use as medical fungicides. Eur. Pat. Appli. 19 (1988).
16. M. Pedersen. Isolation and antimycotic effect of a genuine miconazole beta-cyclodextrin complex. Eur. J. Pharm. Biopharm. 40:19-23 (1994).
17. M. Pedersen, M. Edelsten, V. F. Nielsen, A. Scarpellini, S. Skytte, and C. Slot. Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole. Int. J. Pharm. 90:247-254 (1993).
18. T. Loftsson, M. Brewster, and M. Masson. Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. 2:1-14 (2004).
19. T. Higuchi, and A. Connors. Phase-solubility techniques, Wiley-Interscience, New York, 1965.
20. V. Cavrini, M. D. Pietra, and R. Gatti. Analysis of miconazole and econazole in pharmaceutical formulations by derivative UV spectroscopy and liquid chromatography (HPLC). J. Pharm. Bio. Anal. 7:1535-1543 (1989).
21. L. Ribeiro, T. Loftsson, D. Ferreira, and F. Veiga. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether beta-cyclodextrin binary and ternary complexes. Chem. Pharm. Bull. 51:914-922 (2003).
22. M. D. Veiga, P. J. Diaz, and F. Ahsan. Interactions of griseofulvin with cyclodextrins in solid binary systems. J. Pharm. Sci. 87:891-900 (1998).
23. H. Van Doorne, E. H. Bosch, and C. F. Lerk. Formation and antimicrobial activity of complexes of beta-cyclodextrin and some antimycotic imidazole derivatives. Pharm. Weekblad. 10:80-85 (1988).
24. J. Jacobsen, S. Bjerregaard, and M. Pedersen. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity - drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur. J. Pharm. Biopharm. 48:217-224 (1999).
25. M. N. Reddy, T. Rehana, S. Ramakrishna, K. P. R. Chowdary, and P. V. Diwan. Beta-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies. Aaps Pharmsci. 6:E7 (2004).
26. R. K. Verma, and S. Garg. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J. Pharmaceut. Biomed. 35:449-458 (2004).
27. A. Figueiras, R. A. Carvalho, L. Ribeiro, J. J. Torres-Labandeira, and F. J. B. Veiga. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur. J. Pharm. Biopharm. 67:531-539 (2007).
28. V. Barillaro, G. Dive, E. Ziemons, P. Bertholet, B. Evrard, L. Delattre, and G. Piel. Theoretical and experimental vibrational study of miconazole and its dimers with organic acids: Application to the IR characterization of its inclusion complexes with cyclodextrins. Int. J. Pharm. 350:155-165 (2008).
29. D. Duchêne. Cyclodextrins and their industrial uses, Editions de Santé, Paris, 1987.
30. P. Mura, N. Zerrouk, M. T. Faucci, F. Maestrelli, and C. Chemtob. Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state. Eur. J. Pharma. Biopharm. 54:181-191 (2002).
31. N. B. Naidu, K. P. R. Chowdary, K. V. R. Murthy, V. Satyanarayana, A. R. Hayman, and G. Becket. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharmaceut. Biomed. 35:75-86 (2004).
32. M. Charoenchaitrakool, F. Dehghani, and N. R. Foster. Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-beta-cyclodextrin. Int. J. Pharm. 239:103-112 (2002).
33. M. S. S. Cunha-Filho, B. Dacunha-Marinho, J. J. Torres-Labandeira, R. Martinez-Pacheco, and M. Landin. Characterization of beta-lapachone and methylated beta-cyclodextrin solid-state systems. Aaps PharmSciTech. 8:E68-E77 (2007).